Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MYO_MATRIX

Financiado

Towards a deep knowledge of the extracellular matrix proteins functions in the D...

Towards a deep knowledge of the extracellular matrix proteins functions in the Duchenne Muscular Dystrophy Healthy skeletal muscle has a powerful capacity to regenerate after an injury. On the opposite, muscular dystrophies (MDs) are devastating diseases where these regenerative capacities are overwhelmed and the muscle fibers are prog... ver más

31/12/2025

UNIVERSITE LYON 1...

196K€

Presupuesto del proyecto: 196K€

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-12

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

UNIVERSITE LYON 1 CLAUDE BER...

195.91K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2015-67131-P MIRNAS COMO HERRAMIENTAS MOLECULARES MODULANDO DIFERENCIACIO... 202K€ Cerrado

PID2020-118730RB-I00 EXPLORANDO LAS FUNCIONES DE HDAC11 EN DISTROFIAS MUSCULARES 121K€ Cerrado

StuDySARCOMERE Structure and Cellular Dynamics of the Sarcomere 11M€ Cerrado

PTQ-12-05665 Nuevas aproximaciones terapéuticas in vivo e in vitro para l... 41K€ Cerrado

BES-2010-042490 MECANISMOS REGULADORES DE LA REGENERACION Y EL CRECIMIENTO D... 43K€ Cerrado

SAF2012-38547 REGULATION AND DYSREGULATION OF SKELETAL MUSCLE REGENERATION... 468K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2023-04-12
Fecha Fin: 2025-12-31

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 196K€

Descripción del proyecto Healthy skeletal muscle has a powerful capacity to regenerate after an injury. On the opposite, muscular dystrophies (MDs) are devastating diseases where these regenerative capacities are overwhelmed and the muscle fibers are progressively replaced by fibrosis, leading to muscle loss and finally to death. Fibrosis is the final outcome of excessive production of molecules constituting the extracellular matrix (ECM). However, ECM alterations in MDs have been considered only as the result of muscle damage, the inflammatory response, or an unbalanced degradation/synthesis by fibroblasts. MYO_MATRIX is a 2-year project proposing a innovative point of view by shifting the focus to the extracellular environment, i.e., ECM, as an active partner impacting on muscle cell properties. The final goal is to decipher the role of ECM in skeletal muscle homeostasis and to define the molecular ECM components at work during MDs. Specific objectives include the combination of proteomics, transcriptomics, in situ 3D tissue analyses and ex-vivo functional cell experiments. Comparison of muscles in various conditions (normal, regenerating and dystrophic) will define key molecular determinants controlling beneficial ECM remodeling (in healthy regenerating muscle) versus detrimental fibrosis (in dystrophic muscle). The transdisciplinary (biochemistry and biology) and multilevel (protein, mRNA, cell, tissue) approach will identify new components in MDs. Such an outside-in approach has never been tested so far in skeletal muscle. The project, implemented by a biochemist researcher in a biology host lab (Université Claude Bernard Lyon 1 at Institut NeuroMyoGène), will identify the molecular alterations of ECM in MDs and how they affect the behavior of cells that contribute to muscle homeostasis. The identification of the ECM molecular determinants is the ambition of the project, to propose therapeutic targets for MD patients for whom an effective treatment does not exist yet.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores